Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netazepide for PPI-Induced Hypergastrinemia and Rebound Hyperacidity
NCT02620696Phase 1Completed
- Sponsor
- Trio Medicines Ltd
- Start
- Nov 2009
- Primary completion
- Sep 2010
- Modality
- Allosteric Modulators
01
Overview
Phase 1, randomised, double-blind trial of netazepide in Rebound acid hypersecretion (RAHS) and dyspepsia (6 arms), sponsored by Trio Medicines Ltd. Primary endpoints: Plasma chromogranin A concentrations at 8 weeks and Serum gastrin concentrations at 8 weeks. Started Nov 2009; status: completed.
02
Drugs
netazepide
03
Conditions
Rebound acid hypersecretion (RAHS)dyspepsia
Beyond the preview
Go deeper on NCT02620696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620696.